FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
The patient and local surgical team were located in Gibraltar, about 2,400 kilometers (about 1,500 miles) away. The procedure ...
Artificial intelligence has bounded into the mainstream, into personal lives, classroom assignments and work meetings — so it should be no surprise to find it in doctors’ offices and emergency ...
The research lays a foundation for the possibility that aggressive prostate cancer can probably be detected through a few drops of semen or blood in the long term. Prostate cancer is the most common ...
DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of ...
Our pilot study provides important evidence that microplastic exposure may be a risk factor for prostate cancer,” lead study ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.
Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...
PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results